Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor  by Zhu, Jing et al.
Rapid report
Suppression of macrophage responses to bacterial lipopolysaccharide by
a non-secretory form of secretory leukocyte protease inhibitor
Jing Zhu, Carl Nathan, Aihao Ding *
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, USA
Received 31 March 1999; received in revised form 29 July 1999; accepted 29 July 1999
Abstract
Expression of secretory leukocyte protease inhibitor (SLPI) suppresses the ability of macrophages to respond to bacterial
lipopolysaccharide (LPS). Here, addition of recombinant or native SLPI to the extracellular medium was non-suppressive,
while transfection with a non-secretory form of SLPI was fully suppressive, an effect overcome by treatment with interferon-
Q. A portion of the SLPI produced by untransfected macrophages was localized in the cytosol. Thus, SLPI can act
intracellularly to block macrophage activation by LPS. ß 1999 Elsevier Science B.V. All rights reserved.
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Endotoxic bacterial lipopolysaccharide (LPS), the
major component of the Gram-negative bacterial cell
wall, has a profound impact on the mammalian im-
mune system. Traces of LPS trigger macrophages
and other leukocytes to release a myriad of in£am-
matory mediators [1]. An excessive response to LPS
can lead to septic shock, which has a mortality rate
near 50% and remains the leading cause of death in
intensive care units [2,3]. Thus, it is important to
understand how the response of macrophages to
LPS is regulated.
Several proteins play important roles in initiating
LPS signaling. A serum component, LPS-binding
protein (LBP), catalyzes the transfer of monomeric
LPS from micelles to another LPS-binding protein in
plasma, soluble CD14, and to its cell-bound counter-
part. Both forms of CD14 facilitate LPS uptake
[4^6]. In addition, L2 integrins and Toll-like recep-
tors-2 (TLR2) and TLR4 can mediate LPS signals
[7^9]. Arti¢cially activated TLR2 can signal through
the adaptor proteins MyD88 and TRAF6. Numer-
ous signaling cascades are activated by LPS. How-
ever, the connections among LPS, TLRs and LPS-
activated signal transduction pathways remain un-
clear.
Secretory leukocyte protease inhibitor (SLPI), a
12 kDa disul¢de-rich protein, was discovered as an
epithelial cell product in mucous secretions and char-
acterized as an inhibitor of serine proteases from
leukocytes and the pancreas, such as elastase, cathep-
sin G, trypsin and chymotrypsin [10]. As a major
elastase inhibitor in the respiratory tract, SLPI ap-
pears to exert protective e¡ects in cystic ¢brosis and
emphysema [11^13]. However, the anti-in£ammatory
function of SLPI no longer appears to be limited to
inhibition of proteases. We recently cloned mouse
SLPI (mSLPI) from macrophages and characterized
it as an LPS-induced phagocyte product whose ex-
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pression inhibits macrophage responsiveness to LPS
and to the lipoteichoic acid component of Gram-pos-
itive bacterial cell walls [14,15]. SLPI also exerts anti-
viral [16,17] and anti-bacterial activities [18] and
blocks some responses of human monocytes to LPS
[19].
The secretory nature of SLPI suggested that it was
likely to act as an extracellular mediator to block
macrophage activation. To test this, we pre-incu-
bated mouse HeNC2 macrophages [14] with 1 Wg/
ml of anti-proteolytically active recombinant mSLPI
(Amgen) [20] for 30 min and then stimulated the cells
with 1, 10, 100 or 1000 ng/ml of LPS (List Biolog-
ical). Induction of nitric oxide synthase 2 (NOS 2)
was monitored by measuring nitrite levels in the con-
ditioned media 48 h later (Griess’ reagent) (Fig. 1A).
Surprisingly, recombinant mSLPI exerted no sup-
pressive e¡ect, even though each of two SLPI over-
expressing macrophage cell lines, GG2EE and a sta-
ble mSLPI transfectant of HeNC2 [14], were
hyporesponsive to LPS. Neither increasing the con-
centration of mSLPI to 10 Wg/ml nor prolonging the
pre-incubation to 2 h attenuated LPS-induced nitrite
or tumor necrosis factor (TNF) production in
HeNC2 cells (data not shown). SLPI is di⁄cult to
prepare in an active form, due to its tendency to
oxidation. To test native mSLPI with minimal han-
dling, we co-cultured HeNC2 cells with SLPI-secret-
ing GG2EE cells or with their conditioned medium.
Neither treatment a¡ected nitrite production by
HeNC2 cells in response to LPS (Fig. 1B). These
results are consistent with the inability of recombi-
nant human SLPI to prevent LPS-induced TNF and
interleukin (IL)-10 production by human monocytes
[19].
Since expression of SLPI by various macrophage
populations correlates closely with LPS hyporespon-
siveness and transfection with mSLPI renders macro-
phages resistant to LPS [14], the foregoing results
raised the possibility that SLPI may block LPS re-
sponsiveness by acting at an intracellular site, instead
of or in addition to an extracellular site. To test this
hypothesis, we designed a cytosolic form of mSLPI
(mSLPI-v) by removing the leader sequence, the ¢rst
75 nucleotides, from mSLPI’s open reading frame
(ORF) and replacing it with an ATG starting codon.
mSLPI-v cDNA was incorporated into the p463-Neo
expression vector [21]. The resulting plasmid, p463-
mSLPI-v, or the control plasmid p463-Neo, was elec-
troporated into HeNC2 cells (Gene Pulser, Bio-Rad).
Stable transfectants were selected in neomycin and
cloned by limiting dilution by the procedure used
for full-length mSLPI [14]. Two independent clones
expressing mSLPI-v (mSLPI-v1 and mSLPI-v2) and
one control clone expressing the vector alone (Mock)
were used for functional analysis. By a Northern
blot, mSLPI-v mRNA was easily detected in both
mSLPI-v1 and SLPI-v2 (Fig. 2A). The slower elec-
trophoretic mobility of mSLPI-v mRNA compared
to the endogenous mSLPI message in GG2EE is at-
tributable to an extra 1 kb of sequence acquired from
Fig. 1. Expression of SLPI blocks LPS-induced macrophage ac-
tivation, but addition of exogenous SLPI fails to do so. (A) Re-
combinant mSLPI. HeNC2 (a), HeNC2 pre-treated with re-
combinant mSLPI (1 Wg/ml, 30 min, b), HeNC2 cells stably
transfected with the full-length mSLPI (E) [14] or GG2EE cells
(R) in 96 well culture plates (2U105 cells in 0.1 ml/well) were
incubated with indicated concentrations of LPS for 48 h. (B)
Native SLPI. HeNC2 cells (N, 105 cells) were cultured with the
conditioned medium (CM) of GG2EE cells or with GG2EE
cells (G) themselves (ratio 1:1) in the presence (hatched bars)
or absence (¢lled bars) of 100 ng/ml of LPS. (A and B) The ni-
trite content in the supernatant was determined. Means
þ S.E.M. of triplicates from one of at least three experiments.
Some error bars fall within the symbols.
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the vector. Intracellular retention of mSLPI protein
in mSLPI-v1 and mSLPI-v2 was con¢rmed by West-
ern blotting: mSLPI was present in their cell lysates
but not their conditioned media. In contrast, mSLPI
was detected both in the cell lysate and the condi-
tioned medium of GG2EE cells (Fig. 2A). As ex-
pected, SLPI protein was indistinguishable in Mr
whether derived from mSLPI-v or mSLPI cDNA,
the latter translation product undergoing natural
cleavage of the signal peptide.
To test the e¡ect of intracellular SLPI, we stimu-
lated Mock, mSLPI-vs, GG2EE and parental
HeNC2 cells with 0.1, 1, 10, 100 and 1000 ng/ml of
LPS and measured their conditioned media at 16 h
for TNF (mouse TNF ELISA, Genzyme) and at 48 h
for nitrite. LPS-mediated release of both TNF and
nitrite was greatly reduced in both mSLPI-v1 and
mSLPI-v2, but not in Mock cells (Fig. 2B). The
Northern analysis indicates that SLPI-v a¡ects the
induction of TNF and NOS 2 at the transcription
level (Fig. 2C). Cell viability in these experiments
exceeded 98% by trypan blue exclusion and the
mSLPI-v transfectants were indistinguishable from
the Mock transfectant in both growth rate and mor-
Fig. 2. Characterization of stable transfectants expressing a
non-secretory form of SLPI. (A) mSLPI-v mRNA and protein
expression. Northern blot (NB) and Western blot (WB) analy-
ses for SLPI were performed on GG2EE cells (G), parental
HeNC2 cells (N), vector transfectant (Mock, M) and two
mSLPI-v transfectants (v1 and v2). The mSLPI ORF was used
as a probe for Northern hybridization. mSLPI was immunopre-
cipitated from conditioned media (CM) or cell lysates with rab-
bit anti-mSLPI antiserum and blotted with the same antiserum.
(B) Suppression by intracellular mSLPI of LPS-induced produc-
tion of TNF and nitrite. Cells (105 cells) in 96 well plates were
treated with di¡erent concentrations of LPS. The conditioned
media were collected 16 h later for TNF or 48 h later for ni-
trite determination. HeNC2 (F), GG2EE (b), vector transfec-
tant (8) and mSLPI-v transfectants mSLPI-v1 (R) and
mSLPI-v2 (S). Means þ S.E.M. of triplicates from one of four
similar experiments. Some error bars fall within the symbols.
(C) Suppression of TNF and NOS 2 mRNAs by intracellular
mSLPI. Cells were treated with 100 ng/ml LPS for 8 h. Total
RNA (20 Wg) was analyzed by Northern blotting with cDNA
probes for mouse TNF, NOS 2 or L-actin on the same mem-
brane.
Fig. 3. IFN-Q complements the LPS response defect in mSLPI-
v expressing cells. (A) mSLPI-v1 (R, O) and mSLPI-v2 (b, a)
cells were treated with (O, a) or without (R, b) 10 U/ml of
IFN-Q together with various concentrations of LPS. Nitrite ac-
cumulation was measured 48 h later. Means þ S.E.M. of tripli-
cates from one of three similar experiments. (B) E¡ect of IFN-Q
on the NOS 2 mRNA level. A Northern blot was performed as
in Fig. 2. LPS, 100 ng/ml. IFN-Q, 10 U/ml.
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phology. It is unlikely that trace amounts of SLPI
released from a few dying mSLPI-v transfectants
could account for suppression of the remainder of
the population, since co-culture with SLPI-secreting
cells did not suppress the LPS responses of SLPI-
non-secreting cells (Fig. 1B). These results suggest
that SLPI can act intracellularly to inhibit certain
LPS responses in macrophages.
To exclude that expression of mSLPI-v might
cause non-speci¢c dysfunction in cellular signaling,
we treated mSLPI-v transfectants with LPS in the
presence of mouse interferon-Q (IFN-Q, Genentech).
IFN-Q complements the LPS response defect in
GG2EE cells and in primary macrophages of C3H/
HeJ mice, both of which carry the defective allele of
the lps gene [8,14]. IFN-Q (10 U/ml, 48 h) completely
restored LPS-dependent nitrite production in both
mSLPI-v expressing cells (Fig. 3). Therefore, expres-
sion of mSLPI-v does not interfere with IFN-Q sig-
naling. Moreover, mSLPI-v’s inhibition of LPS sig-
naling is reversible and by that criterion, non-toxic.
To check whether mSLPI can be detected in the
cytosol of non-transfected macrophages, we washed
the cells extensively, lysed them, centrifuged their
post-nuclear supernatant at 100 000Ug for 1 h and
immunoblotted the supernatants and pellets. Fig. 4
shows that mSLPI was detected in the soluble frac-
tion from GG2EE cells as well as that from LPS-
stimulated RAW 264.7 and HeNC2 cells. In fact,
there appeared to be more mSLPI in the soluble
fraction than in the particulate compartment. This
result is consistent with the observation that mSLPI
was abundant in the cytosolic fraction of human
neutrophils [12].
Several mechanisms may account for the presence
of intracellular SLPI. Alternative splicing of SLPI
transcripts may produce a non-secretory form. In
the mouse macrophage cell lines HeNC2, GG2EE
and J774.1, SLPI mRNA appears as a doublet [14].
Because SLPI is a single copy gene in mouse (E.
Martin and A. Ding, unpublished), the doublet is
likely a result of alternative splicing, di¡erential us-
age of polyadenylation sites or various extension of
polyadenylation. Moreover, the genomic sequences
of both human [22] and mouse SLPI (E. Martin
and A. Ding, unpublished) suggest that an exon-in-
tron junction immediately follows the leader se-
quence, consistent with the possibility that a full-
length but non-secretory product could arise from
alternative splicing. Alternatively, a portion of nas-
cent SLPI protein may leak out of the secretory
pathway into the cytosol. Finally, accumulating evi-
dence suggests that some secreted proteins are re-
cruited by cells into the cytosol or even the nucleus
following an interaction with surface receptors, as
distinct from and in addition to their uptake into
membrane-bound intracellular vesicles [23]. Reported
examples include PDGF, FGF, IFN-Q, IL-1 and IL-
5. Some of these possess a nuclear localization signal
whose mutation or deletion does not interfere with
ligand-receptor-binding, but abolishes certain biolog-
ical activities [23]. If SLPI reaches the cytosol by
uptake from the extracellular medium, it would re-
main unexplained why extracellular SLPI failed to
suppress the LPS responses studied.
These ¢ndings raise the question: with what LPS
signaling intermediate might intracellular SLPI bind?
One class of relevant targets for intracellular SLPI
could be proteases. NF-UB activation is essential for
LPS-induced synthesis of many in£ammatory medi-
ators, including NOS 2, TNF, IL-1, IL-2 and IL-6
[24]. At least two steps of NF-UB activation require
proteolysis, the processing of p105 to p50 and the
degradation of the inhibitor I-UB [25]. These events
proceed both via the ubiquitin-proteosome pathway
and by proteosome-independent pathways [26^29].
Inhibitor studies have implicated serine proteases in
I-UB degradation [30,31] and in the induction of
NOS 2 by LPS in macrophages [32,33]. Alternatively,
intracellular SLPI may function independently of its
anti-protease activity, as demonstrated for inhibition
Fig. 4. Detection of mSLPI in the soluble fraction of macro-
phage cytosol. Cell (4U107) lysates from LPS-treated RAW
264.7 (R) and HeNC2 (N) cells or untreated GG2EE (G) cells
were prepared with 50 mM Tris-HCl, pH 7.4, 1% NP-40, 1
mM PMSF. Post-nuclear supernatants (14 000Ug, 30 min) were
subjected to ultracentrifuging (100 000Ug, 60 min) to separate
soluble (sup.) and particulate (ppt.) fractions. SLPI was de-
tected by immunoprecipitation followed by Western analysis as
in Fig. 2.
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of HIV infection of monocytes by extracellular SLPI
[17].
In summary, even though SLPI is predominantly a
secreted protein, macrophages maintain a portion of
their native SLPI in the cytosol. Expression of SLPI
engineered to remain almost entirely within the cell is
just as e¡ective at blocking macrophage activation as
expression of the secretory form. Finally, mouse
macrophages exposed to pure, recombinant, bioac-
tive SLPI or SLPI-containing media from the extrac-
ellular space alone are not blocked from responding
to LPS. These three points combine to suggest that
at least some of SLPI’s anti-in£ammatory e¡ects can
be exerted from inside the phagocyte. Tracking down
intracellular targets of SLPI may shed light on LPS
signaling pathways.
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